Redeye: Bredband2 - Shifting Towards Organic Growth
Redeye retains its positive view of Bredband2 after its Q1 report. Sales and costs were slightly lower than our expectations, where the latter indicates continued cost synergies from the A3 acquisition. Overall, we make minor 2022E and 2023E adjustments, affecting our valuation with a new Base Case of SEK 2.6 per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/